Tozorakimab
mAbexperimentalCOVID-19
Clinical trial activity
15 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
11
Phase 3
5
Phase 4
0
Earliest trial started May 15, 2017 (NCT03096795)
Timeline
Indications
Mechanism of action
- Interleukin-33INHIBITOR
inhibitor - IL33
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650490 ↗
Also known as
- medi3506
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06897748 | Phase 2 | Apr 12, 2025 | AstraZeneca |
| NCT06908577 | Phase 1 | Apr 7, 2025 | AstraZeneca, Parexel |
| NCT06932263 | Phase 2 | Mar 26, 2025 | AstraZeneca |
| NCT06304961 | Phase 1 | Apr 8, 2024 | AstraZeneca |
| NCT06040086 | Phase 3 | Sep 22, 2023 | AstraZeneca |
| NCT05742802 | Phase 3 | Mar 6, 2023 | AstraZeneca |
| NCT05624450 | Phase 3 | Dec 13, 2022 | AstraZeneca |
| NCT05158387 | Phase 3 | Feb 7, 2022 | AstraZeneca |
| NCT05166889 | Phase 3 | Jan 3, 2022 | AstraZeneca |
| NCT05070312 | Phase 1 | Aug 23, 2021 | AstraZeneca |
| NCT04631016 | Phase 2 | Nov 17, 2020 | AstraZeneca |
| NCT04570657 | Phase 2 | Sep 17, 2020 | AstraZeneca |
| NCT04212169 | Phase 2 | Dec 9, 2019 | AstraZeneca |
| NCT04170543 | Phase 2 | Nov 22, 2019 | AstraZeneca |
| NCT03096795 | Phase 1 | May 15, 2017 | MedImmune, Parexel, University of Manchester |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 14 | 14 | 3 | 2019 |
| Parexel | For profit | 2 | 0 | 1 | 2017 |
| MedImmune | For profit | 1 | 1 | 1 | 2017 |
| University of Manchester | Academic/Hospital | 1 | 0 | 1 | 2017 |
4 organizations
Page 1 / 1